Europe — EMA

Osvyrti Accord Healthcare (Denosumab)

Denosumab, the active ingredient in Osvyrti Accord Healthcare, is a monoclonal antibody presented as a solution for subcutaneous injection use.

Denosumab

Request sourcing

Pack/s

What is Denosumab?

Denosumab, the active ingredient in Osvyrti Accord Healthcare, is a monoclonal antibody presented as a solution for subcutaneous injection use. It treats osteoporosis and bone loss conditions in postmenopausal women and men at high risk of fractures. GNH USA supplies Osvyrti Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Osvyrti Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

What is Denosumab used for?

Osvyrti is the ... ... ... ... ... .... ... ... ... ... ... ... ... ... ... ... … … ... … … ... .... .... ... … … …

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →